{"protocolSection": {"identificationModule": {"nctId": "NCT02532179", "orgStudyIdInfo": {"id": "DAIT ICAC-26"}, "organization": {"fullName": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "briefTitle": "Subcutaneous Immunotherapy for Mouse in Adults", "officialTitle": "A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)", "acronym": "SCITMO"}, "statusModule": {"statusVerifiedDate": "2018-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-10"}, "primaryCompletionDateStruct": {"date": "2016-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-08-21", "studyFirstSubmitQcDate": "2015-08-24", "studyFirstPostDateStruct": {"date": "2015-08-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-10-30", "resultsFirstSubmitQcDate": "2017-11-27", "resultsFirstPostDateStruct": {"date": "2017-11-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-02-05", "lastUpdatePostDateStruct": {"date": "2018-03-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "collaborators": [{"name": "Inner-City Asthma Consortium", "class": "NETWORK"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is an open label trial of mouse allergenic extract administered by subcutaneous injection in adults with asthma and mouse sensitivity. The study is designed to evaluate:\n\n* the safety of this therapy when given by injection\n* biomarkers of the immune response and\n* whether the therapy would be effective in treating allergic asthma.", "detailedDescription": "The primary objective of the study is to assess if treatment with mouse subcutaneous immunotherapy (SCIT), using the per protocol allergenic extract doses, is safe. This will be done by determining the rate of related adverse events and serious adverse events in the course of treatment.\n\nSecondary objectives include:\n\n* determination of whether a 24 week treatment with mouse SCIT, using the per protocol allergenic extract doses, will induce a 3-fold increase in mouse-specific serum immunoglobulin E (IgE)\n* determination of whether a 24 week treatment with mouse SCIT, using the per protocol allergenic extract doses, will induce changes in the serum levels of mouse-specific immunoglobulin G (IgG) and immunoglobulin subclass 4 (IgG4)."}, "conditionsModule": {"conditions": ["Asthma", "Perennial Allergic Rhinitis"], "keywords": ["subcutaneous immunotherapy (SCIT)", "glycerinated mouse allergenic extract", "mouse specific IgE", "mouse specific IgG and IgG4", "mouse prick skin test wheal"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Mouse Allergenic Extract", "type": "EXPERIMENTAL", "description": "Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.", "interventionNames": ["Biological: Mouse Allergenic Extract"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Mouse Allergenic Extract", "description": "Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.", "armGroupLabels": ["Mouse Allergenic Extract"], "otherNames": ["mouse epithelial extract", "allergenic extract of Mus musculus"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Reported Adverse Events (AEs)", "description": "Frequency of any AEs tabulated by preferred event term.", "timeFrame": "Baseline (Pre-Treatment) through 24 Weeks of Treatment"}, {"measure": "Number of Reported Serious Adverse Events (SAEs)", "description": "Frequency of any Serious Adverse Events (SAEs) throughout the duration of study participation.", "timeFrame": "Baseline (Pre-Treatment) through 24 Weeks of Treatment"}], "secondaryOutcomes": [{"measure": "Change in Mouse-Specific IgE Antibodies", "description": "Serum Immunoglobulin E (IgE) is an antibody produced by the immune system. If a participant has an allergy, the immune system will respond to that particular allergen by producing IgE antibodies. These antibodies travel to cells that release chemicals, causing allergic reactions.\n\nThis endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgE versus post-baseline mouse-specific serum IgE. The numerator is the geometric mean post-baseline IgE and the denominator is baseline IgE. A ratio of greater than 1 would indicate an increase in IgE throughout the course of the study.", "timeFrame": "Baseline (Pre-Treatment) through Week 24"}, {"measure": "Change in Mouse-Specific IgG Antibodies", "description": "Serum Immunoglobulin G (IgG) is an antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG antibodies.\n\nThis endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG versus post-baseline mouse-specific serum IgG. The numerator is the geometric mean post-baseline IgG and, the denominator is the baseline IgG. A ratio of greater than 1 would indicate an increase in IgG throughout the course of the study.", "timeFrame": "Baseline (Pre-Treatment) to Week 24"}, {"measure": "Change in Mouse-Specific IgG4 Antibodies", "description": "Serum Immunoglobulin G4 (IgG4) is a subtype of antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG4 antibodies.\n\nThis endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG4 versus post-baseline mouse-specific serum IgG4. The numerator is the geometric mean post-baseline IgG4 and, the denominator is the baseline IgG4. A ratio of greater than 1 would indicate an increase in IgG4 antibodies throughout the course of the study.", "timeFrame": "Baseline (Pre-Treatment) to Week 24"}, {"measure": "Change in In-vitro Mouse Antigen Binding to B-cells", "description": "The plan was to analyze serum from cockroach subcutaneous immunotherapy (SCIT)-treated participants to determine if treatment inhibits in-vitro mouse antigen binding to B-cells after 6-months of treatment with mouse SCIT, using the per protocol allergenic extract doses. However, the Sponsor cancelled pursuit of mouse immunotherapy within its program at this time due to assay development complexities and cost; thus, there are no analyses/results for this endpoint/outcome.", "timeFrame": "Baseline (Pre-Treatment) to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "INCLUSION CRITERIA\n\nParticipants who meet any of the following criteria are not eligible for enrollment but may be reassessed. Participants are ineligible if they:\n\n* Are pregnant or lactating. Females must be abstinent or use a medically acceptable birth control method throughout the study (e.g. oral, subcutaneous, mechanical, or surgical contraception);\n* Cannot perform spirometry at Screening;\n* Have an asthma severity classification at Recruitment of severe persistent, using the NAEPP classification, as evidenced by at least one of the following:\n\n  * Requires a dose of greater than 500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid;\n  * Have received more than 2 courses of oral or parenteral corticosteroids within the last 12 months;\n  * Have been treated with depot steroids within the last 12 months;\n  * Have been hospitalized for asthma within the 6 months prior to recruitment;\n  * Have had a life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to recruitment.\n* Do not have access to a phone (needed for scheduling appointments);\n* Have received allergen immunotherapy (SLIT or SCIT) in the last 12 months prior to recruitment or who plan to initiate or resume allergen immunotherapy during the study;\n* Have previously been treated with anti-IgE therapy within 1 year of recruitment;\n* Have received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study;\n* Refuses to sign the Epinephrine Auto-injector Training Form.\n\nEXCLUSION CRITERIA\n\nParticipants who meet any of the following criteria are not eligible for enrollment and may not be reassessed. Participants are ineligible if they:\n\n* Do not primarily speak English;\n* Plan to move from the area during the study period;\n* Have a history of idiopathic anaphylaxis or anaphylaxis grade 2 or higher as defined per protocol;\n* Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that in the opinion of the investigator might interfere with the evaluation of the investigational agent or pose additional risk to the participant;\n* Are using tricyclic antidepressants or beta-adrenergic blocker drugs (both oral and topical);\n* Have not received the seasonal Flu (Influenza) Vaccine if enrolling December through March.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Robert Wood, M.D.", "affiliation": "Johns Hopkins Children's Center: Department of Allergy & Immunology", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Children's National Health System", "city": "Washington", "state": "District of Columbia", "zip": "20010", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Ann and Robert Lurie Children's Hospital of Chicago", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Johns Hopkins Children's Center: Department of Allergy & Immunology", "city": "Baltimore", "state": "Maryland", "zip": "21287", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Henry Ford Health System: Division of Allergy and Immunology", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Information: National Asthma Education and Prevention Program (NAEPP)", "url": "http://www.nhlbi.nih.gov/about/org/naepp"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Subject received depot steroid injection", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "12"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.3", "spread": "7.54"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "10"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}]}, {"title": "Mouse-Specific Serum Immunoglobulin E (IgE) Levels", "description": "Serum Immunoglobulin E (IgE) is an antibody produced by the immune system. If a participant has an allergy, the immune system will respond to that particular allergen by producing antibodies called IgE. These antibodies travel to cells that release chemicals, which cause allergic reactions. We collect mouse-specific serum IgE at baseline and compare with post-baseline IgE in order to determine immune modulation over time. The higher the IgE present in the serum sample, the more likely there is to be a presence of a clinical allergy to the mouse allergen.", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kU/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.34", "spread": "0.45"}]}]}]}, {"title": "Mouse-Specific Serum Immunoglobulin G (IgG) Levels", "description": "Serum Immunoglobulin G (IgG) is an antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing antibodies called IgG. We collect mouse-specific serum IgG at baseline and compare with post-baseline IgG in order to determine immune modulation over time. The higher the IgG present in the serum sample, the more likely there is to be a presence of a clinical allergy to the mouse allergen.", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kU/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.23", "spread": "0.20"}]}]}]}, {"title": "Mouse-Specific Serum Immunoglobulin G4 (IgG4) Levels", "description": "Serum Immunoglobulin G4 (IgG4) is a certain subtype of antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing antibodies called IgG4. We collect mouse-specific serum IgG4 at baseline and compare with post-baseline IgG4 in order to determine immune modulation over time. The higher the IgG4 present in the serum sample, the more likely there is to be a presence of a clinical allergy to the mouse allergen.", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kU/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.08", "spread": "0.35"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Reported Adverse Events (AEs)", "description": "Frequency of any AEs tabulated by preferred event term.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "Baseline (Pre-Treatment) through 24 Weeks of Treatment", "groups": [{"id": "OG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"title": "Total adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Abdominal pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Vomiting", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Injection site swelling", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Peak expiratory flow rate decreased", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Pruritus generalized", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Skin lesion", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Flushing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "PRIMARY", "title": "Number of Reported Serious Adverse Events (SAEs)", "description": "Frequency of any Serious Adverse Events (SAEs) throughout the duration of study participation.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of SAEs", "timeFrame": "Baseline (Pre-Treatment) through 24 Weeks of Treatment", "groups": [{"id": "OG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mouse-Specific IgE Antibodies", "description": "Serum Immunoglobulin E (IgE) is an antibody produced by the immune system. If a participant has an allergy, the immune system will respond to that particular allergen by producing IgE antibodies. These antibodies travel to cells that release chemicals, causing allergic reactions.\n\nThis endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgE versus post-baseline mouse-specific serum IgE. The numerator is the geometric mean post-baseline IgE and the denominator is baseline IgE. A ratio of greater than 1 would indicate an increase in IgE throughout the course of the study.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Pre-Treatment) through Week 24", "groups": [{"id": "OG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3", "lowerLimit": "2.09", "upperLimit": "4.29"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Null hypothesis: there is no difference in immune modulation over time", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Ratio", "paramValue": "3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.09", "ciUpperLimit": "4.29"}]}, {"type": "SECONDARY", "title": "Change in Mouse-Specific IgG Antibodies", "description": "Serum Immunoglobulin G (IgG) is an antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG antibodies.\n\nThis endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG versus post-baseline mouse-specific serum IgG. The numerator is the geometric mean post-baseline IgG and, the denominator is the baseline IgG. A ratio of greater than 1 would indicate an increase in IgG throughout the course of the study.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Pre-Treatment) to Week 24", "groups": [{"id": "OG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.82", "lowerLimit": "2.77", "upperLimit": "5.25"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Null hypothesis: there is no difference in immune modulation over time", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Ratio", "paramValue": "3.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.77", "ciUpperLimit": "5.25"}]}, {"type": "SECONDARY", "title": "Change in Mouse-Specific IgG4 Antibodies", "description": "Serum Immunoglobulin G4 (IgG4) is a subtype of antibody produced by the immune system. If a participant has bacterial or viral infections, the immune system will respond to that particular infection by producing IgG4 antibodies.\n\nThis endpoint/outcome is the ratio of geometric means for baseline mouse-specific serum IgG4 versus post-baseline mouse-specific serum IgG4. The numerator is the geometric mean post-baseline IgG4 and, the denominator is the baseline IgG4. A ratio of greater than 1 would indicate an increase in IgG4 antibodies throughout the course of the study.", "populationDescription": "Intent-to-treat", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Pre-Treatment) to Week 24", "groups": [{"id": "OG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.55", "lowerLimit": "3.87", "upperLimit": "11.06"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Null hypothesis: there is no difference in immune modulation over time", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Ratio", "paramValue": "6.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.87", "ciUpperLimit": "11.06"}]}, {"type": "SECONDARY", "title": "Change in In-vitro Mouse Antigen Binding to B-cells", "description": "The plan was to analyze serum from cockroach subcutaneous immunotherapy (SCIT)-treated participants to determine if treatment inhibits in-vitro mouse antigen binding to B-cells after 6-months of treatment with mouse SCIT, using the per protocol allergenic extract doses. However, the Sponsor cancelled pursuit of mouse immunotherapy within its program at this time due to assay development complexities and cost; thus, there are no analyses/results for this endpoint/outcome.", "populationDescription": "No analysis conducted: Sponsor's decision to not pursue assay development in this study.", "reportingStatus": "POSTED", "timeFrame": "Baseline (Pre-Treatment) to Week 24", "groups": [{"id": "OG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 weight per volume (w/v) glycerinated mouse allergenic extract. Administration of additional dosages were given at study clinician's discretion, up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 w/v, for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation continued until maximum study dose was achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants received one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Enrollment through end of study (up to 24 weeks)", "eventGroups": [{"id": "EG000", "title": "Mouse Allergenic Extract", "description": "Participants received escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route. The first injection contained 0.05 mL of 1:10,000 concentration of 1:20 w/v glycerinated mouse allergenic extract, with proceeding administration of additional dosage at study clinician's discretion, for up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol for the first 11 weeks of the 24-week treatment with two injections per week, separated by at least 2 days. Dose escalation would continue until maximum study dose is achieved in a maximum of 18 weeks. For the remaining time of the 24-week treatment, participants would receive one injection of investigational agent every 2 weeks and were asked to report any symptoms possibly related to the investigation agent to the study sites.", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 6, "otherNumAtRisk": 12}], "otherEvents": [{"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 12}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}]}, {"term": "Pruritus generalised", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}]}, {"term": "Peak expiratory flow rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 12}]}, {"term": "Skin lesion", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director, Clinical Research Operations Program", "organization": "DAIT/NIAID", "email": "DAITClinicalTrialsGov@niaid.nih.gov", "phone": "301-594-7669"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-01-22", "uploadDate": "2017-10-25T14:16", "filename": "Prot_SAP_000.pdf", "size": 1050701}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000001249", "term": "Asthma"}, {"id": "D000065631", "term": "Rhinitis, Allergic"}, {"id": "D000012221", "term": "Rhinitis, Allergic, Perennial"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M30545", "name": "Rhinitis, Allergic", "asFound": "Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M15050", "name": "Rhinitis, Allergic, Perennial", "asFound": "Perennial Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M2853", "name": "Immunomodulating Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}